Kober F, Heiss A, Keminger K, Depisch D
Chirurgische Abteilung, Kaiserin-Elisabeth-Spital, Wien.
Wien Klin Wochenschr. 1990 Apr 27;102(9):274-6.
In a prospective phase II study 15 patients suffering from anaplastic thyroid carcinoma or thyroid sarcoma were treated by surgery and chemotherapy. Chemotherapy varied according to age of the patient and histological subtype of the tumour. The following regimen was used: 100 mg/m2 BSA CDDP, 20 mg/m2 mitoxantrone and 1.5 mg/m2 vincristine. 10 patients responded to chemotherapy, 4 of whom had a complete response. Responders showed a longer mean and median survival time (20.8 months versus 4.5 ms, 15.5 ms vs. 3.8 ms, respectively) than non-responders. In the group responding to chemotherapy no evidence of metachronous metastases was found. Local recurrence was absent only in the patients showing a complete response. Anaplastic carcinomas with areas of differentiated thyroid carcinoma and small cell carcinomas (after exclusion of malignant lymphoma of the thyroid) showed a higher response rate to chemotherapy than spindle or giant cell carcinoma or thyroid sarcoma.
在一项前瞻性II期研究中，15例间变性甲状腺癌或甲状腺肉瘤患者接受了手术和化疗。化疗方案根据患者年龄和肿瘤组织学亚型而有所不同。采用了以下方案：顺铂100mg/m²体表面积、米托蒽醌20mg/m²和长春新碱1.5mg/m²。10例患者对化疗有反应，其中4例完全缓解。有反应者的平均和中位生存时间（分别为20.8个月对4.5个月，15.5个月对3.8个月）比无反应者更长。在对化疗有反应的组中未发现异时转移的证据。仅在完全缓解的患者中未出现局部复发。伴有分化型甲状腺癌区域的间变性癌和小细胞癌（排除甲状腺恶性淋巴瘤后）对化疗的反应率高于梭形或巨细胞癌或甲状腺肉瘤。
